The biologic drug Infliximab is a therapeutic monoclonal antibody. It acts as is an antagonist to TNF alpha, thus is effective in blocking the inflammatory process in numerous chronic inflammatory diseases like Crohn’s disease, ulcerative colitis and inflammatory arthritis. The BÜHLMANN Quantum Blue® Infliximab is the first rapid test to measure infliximab trough level in patient’s serum to allow immediate decision making for potential drug dose adjustments.
MRP8/14 is an early and sensitive marker of inflammation and is released immediately in response to local inflammation. In contrast, other inflammatory markers are generated by downstream pathways and require de novo synthesis. Therefore, MRP8/14 is an ideal target for monitoring disease activity of Rheumatoid Arthritis. The MRP8/14 assays by BÜHLMANN allow for precise and sensitive measurement of this important marker.